Labcorp
Labcorp Holdings Inc. (NYSE: LH) provides clinical laboratory testing and drug development services to healthcare providers, health plans, patients, pharmaceutical and biotechnology companies, medical device and diagnostic companies, and contract research organizations. Its Diagnostics Laboratories (Dx) segment offers… From the company’s description.
In fiscal 2025, Labcorp reported revenue of $13.95B, up 7.2% from fiscal 2024, and net income of $877.70M. Its operating margin was 9.9%, and operations generated $1.64B in cash. Over the twelve months to Jun 30, 2026, revenue was $14.35B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Labcorp does
In the company’s own words
Labcorp Holdings Inc. (NYSE: LH) provides clinical laboratory testing and drug development services to healthcare providers, health plans, patients, pharmaceutical and biotechnology companies, medical device and diagnostic companies, and contract research organizations. Its Diagnostics Laboratories (Dx) segment offers routine and specialty testing, including clinical, anatomic pathology, genetic and genomic tests, as well as patient collection and digital services; its Biopharma Laboratory Services (BLS) segment supports drug development through early-development research, clinical-trial laboratory testing, biomarker services and companion diagnostics. In 2025, Dx generated 78% of revenue and BLS 22%; total revenue was $13.95 billion. The company performed more than 750 million tests during the year, with nearly 71,000 employees serving customers in approximately 100 countries. Its consumer testing channel includes Labcorp OnDemand, and its patient-facing services include Labcorp Patient. Labcorp spun off its former clinical development and commercialization services business, Fortrea, in June 2023. Its website is https://www.labcorp.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Health Services
- Headquarters
- BURLINGTON, NC
- Fiscal year end
- December
- CIK
- 920148
- SIC
- 8071
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Labcorp — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Labcorp · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Labcorp’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Labcorp and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Labcorp's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Labcorp's last four quarterly filings that the numbers alone won't show?”